Sub menu

 
 

ACV meeting statement, Meeting 43, 7 June 2023

Advisory Committee on Vaccines
Published

Section A: Premarket registration applications

At this meeting the committee provided advice on 2 applications under evaluation by the TGA, as below.

Active ingredient (TRADENAME) Sponsor Therapeutic area Application designations Commencement of evaluation
Applications for a 'new vaccine' containing a new active substance (new chemical entity or new biological entity) not currently approved in Australia (Application Type A)

SARS-CoV-2 rS (MVC-COV1901)

(MVC COVID-19 VACCINE)

 Grand Pacific CRO Australia Prevention of COVID-19 Provisional June 2022
Applications for a 'new indication', or additional therapeutic use, for an already approved vaccine (Application Type C)

Influenza virus haemagglutinin

(FLUCELVAX QUAD)

 Seqirus Pty Ltd Prevention of influenza   June 2022

The committee provided advice on:

  • one application for major variation (new dosage form, change/increase in patient group, change in dosage, new strength, new route of administration) (Application Type F)

Further details of the ACV discussion and advice associated with these items may be released within the Australian Public Assessment Reports (AusPARs). To browse all AusPARs see Australian Public Assessment Reports (AusPAR).

Section B: Post-market items

The ACV was not asked to provide advice on a post-market or safety issue.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines (ACV).

or contact the ACV by email ACV@health.gov.au.

Topics
Outcome of

This webpage on the TGA website was printed on 14 Sep 2024. Printed content may be out of date. For up-to-date information, always refer to the digital version: https://www.tga.gov.au/resources/publication/meeting-statements/acv-meeting-statement-meeting-43-7-june-2023

Help us improve the Therapeutic Goods Administration site